Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed TherapiesMaximilian Merz, Uwe Platzbecker, Birthe Schetschorke et al.|Blood|2022Cited by 1
P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myelomaLuise Fischer, Ulrike Köhl, Nora Grieb et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0